Cargando…

Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor

PURPOSE: Thoracic SMARCA4-deficient undifferentiated tumor (SD-UT) is a highly aggressive disease that is nosologically related to but distinct from SMARCA4-deficient non-small cell lung cancer (SD-NSCLC). No standard treatment guidelines were established for SD-UT. This research explored the effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Ying, Yu, Bo, Sun, Haifeng, Zhang, Hongyu, Hu, Zhihuang, Zhang, Yao, Wu, Zhenhua, Sun, Si, Zhao, Xinmin, Yu, Hui, Wu, Xianghua, Li, Yuan, Wang, Jialei, Wang, Huijie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374696/ https://www.ncbi.nlm.nih.gov/pubmed/37115272 http://dx.doi.org/10.1007/s00432-023-04806-y

Ejemplares similares

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Thoracic SMARCA4-deficient undifferentiated tumor
por: Jiang, Jiapeng, et al.
Publicado: (2023)

SMARCA4-deficient undifferentiated thoracic tumor: A case report
por: Kwon, Hee Jung, et al.
Publicado: (2023)

Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
por: Gantzer, Justine, et al.
Publicado: (2022)

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
por: Liu, Chang, et al.
Publicado: (2022)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Thoracic SMARCA4-deficient undifferentiated tumor—a case of an aggressive neoplasm—case report
por: Roden, Anja C.
Publicado: (2021)

A case of thoracic SMARCA4‐Deficient undifferentiated tumor successfully treated with combination Ipilimumab–Nivolumab
por: Nakano, Yoshio, et al.
Publicado: (2022)

Thoracic SMARCA4‐deficient undifferentiated tumor diagnosed by transbronchial mediastinal cryobiopsy: A case report
por: Takemura, Chihiro, et al.
Publicado: (2023)

Thoracic SMARCA4‐deficient undifferentiated tumour: Diagnostic challenges and potential for misdiagnosis in small tissue samples
por: Maartens, Deborah Johanna, et al.
Publicado: (2023)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure
por: Ito, Shotaro, et al.
Publicado: (2021)

SMARCA4‐deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report
por: Utsumi, Takahiro, et al.
Publicado: (2022)

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
por: Rekhtman, Natasha, et al.
Publicado: (2019)

Case Series of SMARCA4-Deficient Undifferentiated Esophageal Carcinoma
por: Ahmed, Omar T, et al.
Publicado: (2022)

Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure
por: Shi, Liyong, et al.
Publicado: (2022)

Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
por: Zhao, Xinmin, et al.
Publicado: (2023)

Correction to: Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNA
por: Zhao, Xinmin, et al.
Publicado: (2023)

Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer
por: Hu, Zhihuang, et al.
Publicado: (2020)

Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report
por: Sheng, Jin, et al.
Publicado: (2023)

Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report
por: Yang, Pan, et al.
Publicado: (2023)

Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review
por: Duan, Huanli, et al.
Publicado: (2021)

SMARCA2/BRM-Deficient Undifferentiated/Rhabdoid Carcinoma of Unknown Primary Site
por: Tono, Yasutaka, et al.
Publicado: (2022)

A dramatic course after the resection of an SMARCA4‐deficient undifferentiated tumour
por: Iguchi, Takafumi, et al.
Publicado: (2022)

Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma
por: Gao, Jie, et al.
Publicado: (2023)

Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
por: Sun, Si, et al.
Publicado: (2017)

The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center
por: Long, Qianqian, et al.
Publicado: (2020)

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Notable Response of SMARCA4-Deficient Undifferentiated Uterine Sarcoma to Palliative Radiation Therapy
por: Kurokawa, Mariko, et al.
Publicado: (2021)

SMARCA4-Deficient Undifferentiated Tumor: A Rare Malignancy With Distinct Clinicopathological Characteristics
por: Al-Shbool, Ghassan, et al.
Publicado: (2022)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Case Report: SMARCA4 (BRG1)-deficient undifferentiated carcinoma of gallbladder with genetic analysis
por: Meng, Xiangpeng, et al.
Publicado: (2023)

Complex Alternative Splicing of the Smarca2 Gene Suggests the Importance of Smarca2-B Variants
por: Yang, Min, et al.
Publicado: (2011)

Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer
por: Liao, Jiatao, et al.
Publicado: (2023)

Is the case really a SMARCA4‐deficient thoracic sarcoma?
por: Kunimasa, Kei
Publicado: (2020)

Synchronous Malignant Gastrointestinal Neuroectodermal Tumor and SMARCA4-Deficient Undifferentiated Carcinoma With Independent Origins in the Small Intestine: A Case Report
por: Chen, Cuimin, et al.
Publicado: (2021)

Response to ‘Is the case really a SMARCA4‐deficient thoracic sarcoma?’
por: Takada, Kohichi, et al.
Publicado: (2020)

SMARCA4-Deficient Undifferentiated Tumor of Lung Mass—A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature
por: Yadav, Ruchi, et al.
Publicado: (2022)

Diagnosis of a SMARCA4 ‐deficient undifferentiated tumor using multigene panel testing: A case report
por: Marumo, Yoshiaki, et al.
Publicado: (2023)

Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab
por: Lin, Yun-Tzu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t53bc8bce9pr7q0soqduohnpe6